Association between low uric acid levels and acute graft-versus-host disease

Annals of Hematology

Volumn 94, Issue 1, 2015, Pages 139-144

  Ostendorf, Benjamin N ^a   Blau, Olga ^a   Uharek, Lutz ^a   Blau, Igor W ^a   Penack, Olaf ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Graft versus host disease; Hematopoietic stem cell transplantation; Inflammation; Uric acid

Indexed keywords

BIOLOGICAL MARKER; URIC ACID;

ADOLESCENT; ADULT; AGED; BLOOD; FEMALE; GRAFT VS HOST DISEASE; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; SURVIVAL RATE; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; URIC ACID; YOUNG ADULT;

EID: 84920068051     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2180-3     Document Type: Article

References (26)

1. Zeiser R, Penack O, Holler E, Idzko M (2011) Danger signals activating innate immunity in graft-versus-host disease. J Mol Med 89:833–845. doi:10.1007/s00109-011-0767-x
2. Penack O, Holler E, van den Brink MRM (2010) Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors. Blood 115:1865–1872. doi:10.1182/blood-2009-09-242784
3. Penack O, Smith OM, Cunningham-Bussel A et al (2009) NOD2 regulates hematopoietic cell function during graft-versus-host disease. J Exp Med 206:2101–2110. doi:10.1084/jem.20090623
4. Wilhelm K, Ganesan J, Müller T et al (2010) Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med 16:1434–1438. doi:10.1038/nm.2242
5. Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425:516–521. doi:10.1038/nature01991
6. Martinon F, Pétrilli V, Mayor A et al (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241. doi:10.1038/nature04516
7. Cannell PK, Herrmann RP (1992) Urate metabolism during bone marrow transplantation. Bone Marrow Transplant 10:337–339
8. Jankovic D, Ganesan J, Bscheider M et al (2013) The Nlrp3 inflammasome regulates acute graft-versus-host disease. J Exp Med 4:499. doi:10.1182/blood-2007-06-094482
9. Yeh AC, Brunner AM, Spitzer TR, et al (2014) Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation. Biol Blood Marrow Trans 1–5. doi:10.1016/j.bbmt.2014.02.003
10. Abraham A, Drory VE (2014) Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol 1–6. doi:10.1007/s00415-014-7331-x
11. Andreadou E, Nikolaou C, Gournaras F et al (2009) Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin Neurol Neurosurg 111:724–728. doi:10.1016/j.clineuro.2009.06.012
12. Auinger P, Kieburtz K, McDermott MP (2010) The relationship between uric acid levels and Huntington's disease progression. Mov Disord 25:224–228. doi:10.1002/mds.22907
13. Cankurtaran M, Yesil Y, Kuyumcu ME et al (2013) Altered levels of homocysteine and serum natural antioxidants links oxidative damage to Alzheimer's disease. J Alzheimers Dis 33:1051–1058. doi:10.3233/JAD-2012-121630
14. Casper J, Holowiecki J, Trenschel R et al (2012) Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning. Bone Marrow Transplant 47:1171–1177. doi:10.1038/bmt.2011.242
15. Sato M, Nakasone H, Oshima K et al (2012) Prediction of transplant-related complications by C-reactive protein levels before hematopoietic SCT. Bone Marrow Transplant 48:1–5. doi:10.1038/bmt.2012.193
16. Armand P, Gibson CJ, Cutler C et al (2012) A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 120:905–913. doi:10.1182/blood-2012-03-418202
17. Nannya Y, Kataoka K, Hangaishi A et al (2011) The negative impact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk. Transpl Int 24:469–476. doi:10.1111/j.1432-2277.2011.01229.x
18. Przepiorka D, Weisdorf D, Martin P, et al (1995) 1994 Consensus Conference on Acute GVHD Grading. In: Bone marrow transplant. pp 825–828
19. Holler E, Hahn J, Andreesen R, Rogler G (2008) NOD2/CARD15 polymorphisms in allogeneic stem-cell transplantation from unrelated donors: T depletion matters. J Clin Oncol. doi:10.1200/JCO.2007.14.9005
20. Jankovic D, Ganesan J, Bscheider M et al (2013) The Nlrp3 inflammasome regulates acute graft-versus-host disease. J Exp Med 210:1899–1910. doi:10.1084/jem.20130084
21. Jin Jun Luo XL (2013) A double-edged sword: uric acid and neurological disorders. Brain Disord Ther. doi:10.4172/2168-975X.1000109
22. Ames BN, Cathcart R, Schwiers E (1981) Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis.
23. Azar Y, Shainer R, Almogi-Hazan O et al (2013) Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model). Biol Blood Marrow Transplant 19:519–528. doi:10.1016/j.bbmt.2012.12.011
24. Amer J, Weiss L, Reich S et al (2007) The oxidative status of blood cells in a murine model of graft-versus-host disease. Ann Hematol 86:753–758. doi:10.1007/s00277-007-0321-7
25. Suh JH, Kanathezhath B, Shenvi S et al (2014) Thiol/redox metabolomic profiling implicates GSH dysregulation in early experimental graft versus host disease (GVHD). PLoS ONE 9:e88868. doi:10.1371/journal.pone.0088868
26. Nagler R, Barness-Hadar L, Lieba M, Nagler A (2006) Salivary antioxidant capacity in graft versus host disease. Cancer Invest 24:269–277. doi:10.1080/07357900600634013